Sorrento Therapeutics, Inc.’s BTK inhibitor, abivertinib, has potential to fill the vacuum in marginal zone lymphoma (MZL) that AbbVie Inc. and Johnson & Johnson left in April when they withdrew the indication for the BTK/EGFR inhibitor, Imbruvica (imbruvica), in that disease as well as mantle cell lymphoma (MCL) following lackluster Phase III confirmatory trial results. Sorrento could be in an especially strong position if it can continue to show a favorable safety profile.
Sorrento plans to move abivertinib into pivotal Phase III development in China following the announcement of successful Phase IIa results,...